Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imvotamab in Relapsed/Refractory Non-Hodgkin Lymphoma
NCT04082936Phase 2Terminated
- Sponsor
- IGM Biosciences
- Start
- Sep 2019
- Primary completion
- Feb 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of imvotamab in non-Hodgkin lymphoma (NHL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and 2 more (6 arms), sponsored by IGM Biosciences. Primary endpoints: Overall Frequency of Adverse Events and Overall Response Rate. Started Sep 2019; status: terminated.
02
Drugs
imvotamab
03
Conditions
non-Hodgkin lymphoma (NHL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04082936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04082936.